30 closest matches · ranked by relevance
Breast Cancer
Primary: Number of Participants With Breast Cancer Recurrence, Including Recurrent DCIS and New Contralateral Tumours — 103; 120 Participants — p=0.33
DCIS
Primary: Number of Participants With a Change in Ki-67 Level — 15; 5; 3 Participants — p=0.004
Breast Cancer · LCIS · DCIS
Primary: Quality of Life as Measured by the Breast Q — 61.9; 57.6; 74.2; 64.2 score on a scale
Breast Cancer
Primary: Overall Clinical Response to the Dose Dense Regimen — 43 Participants
Breast Neoplasms · Breast Cancer · Adenocarcinomas
Primary: Number of Participants With Cardiac Toxicity — 6; 7; 6; 6 Participants
Breast Cancer · Invasive Breast Cancer
Primary: Change in Baseline of Cancer Cell Protein Levels of Human Epidermal Growth Factor Receptor (HER) Family Members (HER1-4) Following Neoadjuvant Endocrine Therapy. — 1…
Breast Cancer
Primary: Pathological Response for Basal Group 2 — 16; 14; 5; 11 Participants
Breast Cancer
Primary: Percentage of Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Status in Breast Cancer Specimens Using Immunohistochemistry (IHC) and Silver In-Situ…
Breast Cancer · Ductal Carcinoma in Situ - Category
Primary: 18F-FES Uptake in DCIS — 1.43 SUV
Breast Cancer
Primary: Disease-free Survival — 64; 71; 70 percentage of participants
High-grade Salivary Gland Carcinoma · High-grade Salivary Gland Mucoepidermoid Carcinoma · Low-grade Salivary Gland Carcinoma
Primary: Objective Response Rates (Partial and Complete Responses) — 0 participants
Breast Cancer
Primary: Assess the Ability of the HD PET/CT to Predict Final Histopathologic NAC Response.
Disseminated HER2+ Breast Cancer
Primary: The Patient Clinical Profile (General Clinical Data and Breast Cancer Characteristics) — 63.5; 48.8; 84.1; 41.1 percentage of participants
Invasive Breast Cancer
Primary: 5 Year Distant Disease Free Survival (DDFS) Assessed as Rate of Patients Without Distant Metastases in Subgroup Luminal A vs. Combined Subgroup (Luminal B, HER2…
Breast Cancer
Primary: Number of Participants With Tumor Response (Stable Disease) — 5 participants
Breast Cancer
Primary: Median Change in 6-month Tumor Volume Compared to Baseline Using Mammography — -5.0 change in tumor volume (mm) — p=0.07
Breast Cancer
Primary: Number of Participants With a Pathological Complete Response — 21; 24; 99; 89 participants
Breast Cancer · Chest Wall Disease
Primary: Disease Control Rate (DCR) at 18 Weeks — 20; 17 percentage of participants
Metastatic Breast Cancer
Primary: Number of Participants With and Without Progression Free Survival (PFS) Events — 92; 30 Participants
Breast Cancer
Primary: Change in Ki-67 in Breast Tissue of High-Risk Women
Breast Cancer
Primary: Progression-free Survival (PFS) — 14.4; 19.3 Months
Breast Cancer
Primary: Number of Participants Who Experienced Toxicity to the Vaccine — 0; 0 Participants
Breast Cancer
Primary: The Safety and Tolerability of Protocol Treatment, Defined as the Percentage of Patients Experiencing Severe or Life-threatening Side Effects Per CTCAE Version 3.0. — 40…
Breast Cancer
Primary: Mean Total MRI Functional Tumor Volume (FTV) Change From Baseline to Month 3 (V3) — -1.93 cubic centimeters — p=<0.001
Breast Cancer
Primary: Number of Patients With Pathological Complete Response — 2 participants
Breast Cancer
Primary: Number of Participants With Adverse Events and Serious Adverse Events — 25; 21; 4; 2 Participants
Breast Neoplasms
Primary: Pathologic Complete Response (pCR) — 25 Participants
Breast Cancer · Menopausal Symptoms
Primary: Endoxifen Concentrations in Participants Receiving Tamoxifen Citrate Dose of 20 mg or 40 mg Stratified by the Metabolizing CYP2D6 Genotypes — 8.4; 10.00; 7.10; 3.42 ng/mL
Breast Cancer
Primary: Clinical Response — 3; 30; 11; 3 participants
Breast Cancer
Primary: Progression-free Survival (PFS) — 6.6; 3.8 Months — p=0.12